The EBMT will be actively participating in the 64th ASH Annual Meeting & Exposition that will be held December 10-13, in New Orleans, Louisiana, USA. This in-person event will be broadcast virtually and access to the meeting’s virtual platform is included with registration.
The EBMT will present 41 communications in the different oral or poster sessions.
You will find below the list of these abstracts including title, time and location of presentations. You can click on the title to view the full abstract from the ASH website.
Congratulations to all co-authors and thank you all for your continuous support!
Oral Sessions
Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party
Type: Paper
Number: 302
Presenter: Ali Bazarbachi
Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Molecular Features and Response to Treatment in AML
Time and Location: Saturday, December 10, 2022: 4:00 PM-5:30 PM
388-390 (Ernest N. Morial Convention Center)
Outcome of Haematopoietic Cell Transplantation in 813 Children with Fanconi Anaemia: A Study on Behalf of the EBMT Severe Aplastic Anaemia Working Party and Paediatric Disease Working Party
Type: Paper
Number: 266
Presenter: Su Han Lum
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Clinical Outcome: Real World Studies Based on Database Analyses
Time and Location: Saturday, December 10, 2022: 2:00 PM-3:30 PM
391-392 (Ernest N. Morial Convention Center)
Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT
Type: Paper
Number: 371
Presenter: Thomas Luft
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities III
Time and Location: Saturday, December 10, 2022: 4:00 PM-5:30 PM
343-345 (Ernest N. Morial Convention Center)
Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation – a Registry Study on Behalf of the EBMT Acute Leukemia Working Party
Type: Paper
Number: 871
Presenter: Jesus Duque Afonso
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities II
Time and Location: Monday, December 12, 2022: 2:45 PM-4:15 PM
393-396 (Ernest N. Morial Convention Center)
Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
Type: Paper
Number: 957
Presenter: Philipp Berning
Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Mature T- and NK-cell Lymphomas: Prospective Trials and a Retrospective Analysis
Time and Location: Monday, December 12, 2022: 4:30 PM-6:00 PM
271-273 (Ernest N. Morial Convention Center)
Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study
Type: Paper
Number: 776
Presenter: Akshay Sharma
Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence I
Time and Location: Monday, December 12, 2022: 10:30 AM-12:00 PM
243-245 (Ernest N. Morial Convention Center)
Poster Session
Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Pooled Analysis of Defifrance and EBMT PASS Registries
Type: Paper
Number: 2067
Presenter: Mohamad Mohty
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I
Time and Location: Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)
CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Type: Paper
Number: 4663
Presenter: Eolia Brissot
Program: Oral and Poster Abstracts
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
Time and Location: Monday, December 12, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Activity of Ex Vivo Graft and DLI Engineering within the Last Decade Increases, a Survey from the EBMT Cellular Therapy & Immunobiology Working Party
Type: Paper
Number: 2068
Presenter: Moniek de Witte
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I
Time and Location: Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)
Handling of Allogeneic HPC Grafts in European Transplant Centers during the COVID-19 Pandemic – a Survey from the Infectious Diseases and Cellular Therapy & Immunobiology Working Parties of the EBMT
Type: Paper
Number: 4682
Presenter: Nina Worel
Program: Oral and Poster Abstracts
Session: 711. Cell Collection and Processing: Poster III
Time and Location: Monday, December 12, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working Party
Type: Paper
Number: 2576
Presenter: Stefano Giardino
Program: Oral and Poster Abstracts
Session: 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II
Time and Location: Sunday, December 11, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study
Type: Paper
Number: 3443
Presenter: Alberto Mussetti
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
Time and Location: Sunday, December 11, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party
Type: Paper
Number: 2034
Presenter: Olaf Penack
Program: Oral and Poster Abstracts
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I
Time and Location: Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)
Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys
Type: Paper
Number: 4672
Presenter: Olaf Penack
Program: Oral and Poster Abstracts
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III
Time and Location: Monday, December 12, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT
Type: Paper
Number: 4732
Presenter: Mitja Nabergoj
Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III
Time and Location: Monday, December 12, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT
Type: Paper
Number: 4758
Presenter: Anna Sureda
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location: Monday, December 12, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Conditioning Regimen Intensity and Donor Choice Do Not Impact Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in First Complete Remission (CR1): An EBMT Analysis
Type: Paper
Number: 2126
Presenter: Razan Mohty
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Time and Location: Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)
Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
Type: Paper
Number: 2057
Presenter: Elif Ince
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I
Time and Location: Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)
A Second Haploidentical Stem Cell Transplantation (HAPLO-SCT2) after Relapse from First Haplo-SCT Is Feasible and Produces Results That Are Comparable to Data Reported after Second SCT in an HLA-Matched Setting - a Study on Behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Type: Paper
Number: 3447
Presenter: Giuliano Filippini Velazquez
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
Time and Location: Sunday, December 11, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin’s Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party
Type: Paper
Number: 2918
Presenter: Maria Carmen Martinez Munoz
Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II
Time and Location: Sunday, December 11, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021
Type: Paper
Number: 4680
Presenter: Patrick Hayden
Program: Oral and Poster Abstracts
Session: 711. Cell Collection and Processing: Poster III
Time and Location: Monday, December 12, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
Type: Paper
Number: 2114
Presenter: Olivier Tournilhac
Program: Oral and Poster Abstracts
Session: 731. Autologous Transplantation: Clinical and Epidemiological: Poster I
Time and Location: Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)
Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT
Type: Paper
Number: 2095
Presenter: Ann-Kristin Schmälter
Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster I
Time and Location: Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)
Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3-ITD and Wild Type NPM1: A Report from the EBMT Acute Leukemia Working Party
Type: Paper
Number: 2136
Presenter: Ali Bazarbachi
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Time and Location: Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)
Current Use of Androgens in Bone Marrow Failure Disorders: A Report from the Severe Aplastic Anemia Working Party (SAAWP) of the European Society of Blood and Marrow Transplantation (EBMT)
Type: Paper
Number: 2569
Presenter: Simona Pagliuca
Program: Oral and Poster Abstracts
Session: 508. Bone Marrow Failure: Acquired: Poster II
Time and Location: Sunday, December 11, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT
Type: Paper
Number: 2124
Presenter: Martina Calabrò
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Time and Location: Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)
The EBMT Disease Risk Stratification System (DRSS) Allows Prediction of Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Type: Paper
Number: 3453
Presenter: Yasmine Kadri
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
Time and Location: Sunday, December 11, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT
Type: Paper
Number: 4761
Presenter: Kordelia Barbullushi
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location: Monday, December 12, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
Type: Paper
Number: 2289
Presenter: Laurent Garderet
Program: Oral and Poster Abstracts
Session: 905. Outcomes Research—Lymphoid Malignancies: Poster I
Time and Location: Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)
Graft-Versus-Host-Disease Prophylaxis with ATG or Ptcy in Patients with Lymphoproliferative Disorders Undergoing Reduced Intensity Conditioning Regimen 9/10 Mmud HCT
Type: Paper
Number: 3403
Presenter: Annalisa Paviglianiti
Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II
Time and Location: Sunday, December 11, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
Type: Paper
Number: 2111
Presenter: Laurent Garderet
Program: Oral and Poster Abstracts
Session: 731. Autologous Transplantation: Clinical and Epidemiological: Poster I
Time and Location: Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)
Comparable Outcomes Following Non-First-Degree and First-Degree Related Donor Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia Patients in Complete Remission: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Type: Paper
Number: 4757
Presenter: Yishan Ye
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location: Monday, December 12, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)
Type: Paper
Number: 3344
Presenter: Bertram Glass
Program: Oral and Poster Abstracts
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II
Time and Location: Sunday, December 11, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study
Type: Paper
Number: 4895
Presenter: Clemence Aldebert
Program: Oral and Poster Abstracts
Session: 904. Outcomes Research—Non-Malignant Conditions: Poster III
Time and Location: Monday, December 12, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma
Type: Paper
Number: 2130
Presenter: Sarah Lawless
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Time and Location: Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)
Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis
Type: Paper
Number: 4759
Presenter: Juan Carlos Hernandez Boluda
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Time and Location: Monday, December 12, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Early Hepatotoxicity in Patients with Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
Type: Paper
Number: 3376
Presenter: Marie Robin
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II
Time and Location: Sunday, December 11, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML – Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI
Result Type: Paper
Number: 4690
Presenter: Rama Al Hamed
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III
Time and Location: Monday, December 12, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
Type: Paper
Number: 3638
Presenter: Molly Tokaz
Program: Oral and Poster Abstracts
Session: 906. Outcomes Research—Myeloid Malignancies: Poster II
Time and Location: Sunday, December 11, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation
Type: Paper
Number: 3450
Presenter: Frederic Baron
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
Time and Location: Sunday, December 11, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)
Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Type: Paper
Number: 3373
Presenter: Arnon Nagler
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II
Time and Location: Sunday, December 11, 2022: 6:00 PM-8:00 PM
Hall D (Ernest N. Morial Convention Center)